December 21, 2017 / 12:00 PM / 7 months ago

BRIEF-Ambrx And Tracon Pharma Announce Commercialization Agreement For TRC105 In China

Dec 21 (Reuters) - Tracon Pharmaceuticals Inc:

* AMBRX AND TRACON PHARMACEUTICALS ANNOUNCE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR TRC105 IN CHINA

* AMBRX INC - ENTERED INTO LICENSING AGREEMENT FOR DEVELOPMENT & COMMERCIALIZATION OF TRACON’S PROPRIETARY ENDOGLIN ANTIBODY, TRC105 IN CHINA

* AMBRX SAYS TRANSACTION GRANTS AMBRX EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE TRC105 IN ALL INDICATIONS IN CHINA AND TAIWAN

* AMBRX SAYS UNDER DEAL TERMS, TRACON WILL RECEIVE AN UPFRONT PAYMENT OF $3 MILLION

* AMBRX SAYS TRACON IS ALSO ELIGIBLE TO RECEIVE TIERED ROYALTIES FROM HIGH SINGLE DIGITS TO LOW TEENS ON NET SALES OF TRC105 IN AMBRX TERRITORIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below